Kanamycin-resistant tumor necrosis factor recombinant expression vector, recombinant bacterium and application

By using the kanamycin resistance gene and E. coli temperature-sensitive expression vector in the tumor necrosis factor recombinant expression vector, the kanamycin resistance tumor necrosis factor recombinant engineering bacteria were constructed, and the instability of TNF plasmid expression and low yield were solved. The problem of this has achieved high yield and safety improvement, and avoided penicillin allergic reactions.

CN118895291APending Publication Date: 2024-11-05SHANGHAI WEIKE BIOPHARML
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410801412.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-20
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

In the prior art, the expression of tumor necrosis factor (TNF) plasmids is unstable, the yield is low, and penicillin-resistant engineered bacteria may cause allergic reactions in the production process, affecting product safety.

Method used

Using the kanamycin-resistant tumor necrosis factor recombinant expression vector, using the kanamycin gene as a resistance gene, combining the temperature-sensitive expression vector of E. coli, inserting the human tumor necrosis factor gene and kanamycin with a promoter Genes, construct recombinant engineering bacteria, ensure stable expression and high yield of plasmids during fermentation, while avoiding penicillin allergic reactions.

Benefits of technology

The fermentation yield of tumor necrosis factor was significantly improved, the plasmid loss rate was 0%, and the expression volume was greater than the previous stage of 40%, which improved the safety and stability of the product.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118895291A_ABST
    Figure CN118895291A_ABST
Patent Text Reader

Abstract

The invention discloses a kanamycin-resistant tumor necrosis factor recombinant expression vector, recombinant bacteria and application, the recombinant expression vector takes an escherichia coli temperature-sensitive expression vector lacking a resistance gene as a skeleton, and a human tumor necrosis factor gene or a recombinant human tumor necrosis factor gene and a kanamycin gene with a promoter are inserted into the skeleton. According to the tumor necrosis factor expression vector disclosed by the invention, the kanamycin gene is used as a resistance gene, and the plasmid of the prepared recombinant engineering bacterium is stably expressed during fermentation, so that the yield of the tumor necrosis factor is remarkably improved; meanwhile, penicillin anaphylaxis damage possibly caused by penicillin added in the production process of the penicillin-resistant engineering bacteria to human bodies is also avoided, and the safety of the product is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of bioengineering, and in particular to a kanamycin-resistant tumor necrosis factor recombinant expression vector, a recombinant bacterium and an application thereof. Background Art

[0002] Tumor Necrosis Factor (TNF) is a cytokine produced by immune cells (such as macrophages and T cells) with multiple biological functions. It is mainly divided into two types: TNF-α and TNF-β. TNF plays an important role in immune response and inflammation. It can trigger cell apoptosis, induce inflammatory response, and regulate the activity of immune cells. In addition, TNF is also involved in regulating cell proliferation, differentiation and apoptosis, and has a certain effect on the growth and spread of tumor cells. In certain disease states, overexpression of TNF may lead to excessive inflammatory response, thereby causing disease. TNF has also been widely studied and has become a target for the treatment of certain autoimmune diseases (such as rheumatoid arthritis, Crohn's disease, etc.) and tumors.

[0003] Recombinant Mutant Human Tumor Nerosis Factor for Injection (RMH-TNF) is referred to as TNF in this article. The mechanism of action is: destroying the blood supply of tumor tissue, causing hemorrhage and necrosis of tumor tissue; injecting into the tumor body can directly kill cancer cells and inhibit the growth of cancer cells; enhance the anti-tumor effect of the patient's immune system. The mature human TNF molecule is composed of 157 amino acids. The spatial structure of TNF is a tight trimer structure composed of three identical TNF monomers. Each monomer TNF is wedge-shaped, 50A long and 30A wide at the widest point. It is composed of two β-sandwich structures parallel to each other in opposite directions, which is very similar to the jelly-roll motif of the viral envelope protein.

[0004] At present, microbial fermentation is a means of producing TNF. For example, in the invention with publication number CN1055200A, genetic engineering technology was used to obtain the tumor necrosis factor gene TNF-α from the PHT1 plasmid and clone it into the streptomycin pIJ486 vector to obtain the recombinant plasmid PIJT7 with neomycin neo resistance. The patent application with publication number CN97125202.5 discloses a recombinant human tumor necrosis factor and a preparation method, and an engineered bacterium containing a penicillin-resistant recombinant human tumor necrosis factor expression vector was constructed for fermentation. However, it was found in production that the plasmid in this technology is usually unstable in expression and easy to lose, and the TNF production after fermentation needs to be improved.

[0005] Therefore, how to provide a stable expression vector to increase the fermentation yield of TNF is a problem that needs to be solved.

[0006] In view of this, the present invention is proposed. Summary of the invention

[0007] The technical problem to be solved by the present invention is to overcome the deficiencies of the prior art and provide a kanamycin-resistant tumor necrosis factor recombinant expression vector, recombinant bacteria and application. The tumor necrosis factor expression vector of the present invention adopts kanamycin gene as a resistance gene, and the prepared recombinant engineering bacteria stably express plasmids during fermentation, and the yield of tumor necrosis factor is significantly improved. At the same time, it also avoids the penicillin allergic reaction damage to the human body caused by the addition of penicillin in the production process of penicillin-resistant engineering bacteria, thereby improving the safety of the product.

[0008] In order to solve the above technical problems, the basic concept of the technical solution adopted by the present invention is:

[0009] The invention provides a kanamycin-resistant tumor necrosis factor recombinant expression vector. The recombinant expression vector uses an Escherichia coli temperature-sensitive expression vector lacking a resistance gene as a skeleton, and is inserted with a human tumor necrosis factor gene or a recombinant human tumor necrosis factor and a kanamycin gene with a promoter.

[0010] The tumor necrosis factor expression vector of the present invention adopts kanamycin gene as resistance gene, and the prepared recombinant engineering bacteria stably express plasmid during fermentation, and the yield of tumor necrosis factor is significantly improved. At the same time, it also avoids the penicillin allergic reaction damage to human body caused by adding penicillin in the production process of penicillin-resistant engineering bacteria, thereby improving the safety of the product.

[0011] In the kanamycin gene with a promoter, the promoter is the promoter of the kanamycin gene itself.

[0012] In a further embodiment, the Escherichia coli temperature-sensitive expression vector lacking a resistance gene is a pJLA503 expression vector that does not contain a resistance gene.

[0013] In a further embodiment, the amino acid sequence corresponding to the recombinant human tumor necrosis factor has 151 amino acids in total, and compared with the prototype human tumor necrosis factor, the amino acid residues 1 to 7 at the amino terminal are deleted, the amino acid residues 8, 9, and 10 at the amino terminal are replaced by Arg, Lys, and Arg, and at least one of Ala and Leu at the carboxyl terminal is replaced by one of Gln, Ser, Gly, Thr, Tyr, and Asn. Preferably, Ala or Leu at the carboxyl terminal is replaced by Gln.

[0014] In a further embodiment, the kanamycin-resistant tumor necrosis factor expression vector is based on the pJLA-hTNFNC expression vector, and the ampicillin gene fragment is replaced by a kanamycin gene fragment with a promoter.

[0015] In a further embodiment, the pJLA-hTNFNC expression vector is the vector disclosed in the patent application CN1220997A.

[0016] The present invention also provides a method for constructing the kanamycin-resistant tumor necrosis factor recombinant expression vector as described above, comprising:

[0017] The kanamycin gene and human tumor necrosis factor gene or recombinant human tumor necrosis factor gene fragment with a promoter are amplified and inserted into a temperature-sensitive expression vector of Escherichia coli lacking a resistance gene by means of enzyme cutting and ligation.

[0018] A further solution includes: amplifying the kanamycin gene with a promoter, and replacing the ampicillin gene fragment with a promoter in the pJLA-hTNFNC expression vector by enzyme cutting and ligation.

[0019] The present invention also provides a recombinant bacterium comprising the kanamycin-resistant tumor necrosis factor recombinant expression vector as described above.

[0020] In a further embodiment, the recombinant bacteria is Escherichia coli;

[0021] In a further embodiment, the recombinant bacterium is Escherichia coli HMS174 (DE3).

[0022] The present invention also provides a use of the kanamycin-resistant tumor necrosis factor recombinant expression vector or the recombinant bacteria in producing tumor necrosis factor.

[0023] The present invention also provides a use of the kanamycin-resistant tumor necrosis factor recombinant expression vector or the recombinant bacteria described above in increasing the production of tumor necrosis factor.

[0024] The recombinant plasmid constructed by the above method contains kanamycin resistance and is more stable in the subsequent fermentation process.

[0025] After adopting the above technical solution, compared with the prior art, the beneficial effects of the present invention are mainly reflected in:

[0026] (1) The tumor necrosis factor expression vector of the present invention uses the kanamycin gene as a resistance gene, and the prepared recombinant engineered bacteria stably express the plasmid during fermentation, and the production of tumor necrosis factor is significantly improved. At the same time, it also avoids the penicillin allergic reaction damage to the human body caused by the addition of penicillin to the penicillin-resistant engineered bacteria during the production process, thereby improving the safety of the product.

[0027] (2) The present invention found that during the fermentation process, the engineered bacteria containing the kanamycin-resistant tumor necrosis factor expression vector had very good plasmid stability, and the plasmid loss rate and expression level were better than those of the penicillin-resistant gene bacterial fermentation at the original temperature. The plasmid loss rate of the present invention was 0%, that is, no plasmid was lost, and the fermentation expression level was higher than before, both greater than 40%.

[0028] The specific implementation modes of the present invention are further described in detail below in conjunction with the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] The accompanying drawings are part of the present invention and are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention, but do not constitute an improper limitation of the present invention. Obviously, the drawings described below are only some embodiments. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work. In the drawings:

[0030] Figure 1 The structure map of the recombinant expression vector of the present invention;

[0031] Figure 2 The sequencing result of clone E56612A corresponding to the constructed C7189424G0-2 (promoter+kan_h-TNF-NC) is shown in Figure 1. The sequence determined includes promoter+kanamycin gene+TNF gene sequence.

[0032] Figure 3 The gel electrophoresis pattern of the recombinant expression vector digestion product. M: KBLadder; Lane 1: C7189424G0-2 plasmid; Lane 2: C7189424G0-2 plasmid digested with Pvul and Xhol;

[0033] Figure 4 Flow chart of the protein purification process;

[0034] Figure 5 This is the SDS-PAGE electrophoresis diagram of DEAE column sample detection;

[0035] Figure 6 This is the electrophoresis diagram of S-100 chromatography protein electrophoresis detection.

[0036] Figure 7 This is the SDS-PAGE electrophoresis diagram comparing the protein amounts before and after ultrafiltration desalting in Experimental Example 2.

[0037] It should be noted that these drawings and textual descriptions are not intended to limit the conceptual scope of the present invention in any way, but are intended to illustrate the concept of the present invention for those skilled in the art by referring to specific embodiments. DETAILED DESCRIPTION

[0038] In order to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. The following embodiments are used to illustrate the present invention but are not used to limit the scope of the present invention.

[0039] 1. Construction of recombinant expression vector

[0040] 1. Design "promoter+kan" synthetic primers according to the sequence, amplify the "promoter+kan" fragment, and clone it into the BspHI site of h-TNF-NC (C4582HL070-3) by recombination to obtain the product C7189424G0-2

[0041] (promoter+kan_h-TNF-NC), vector map as Figure 1 shown.

[0042] It should be noted that the h-TNF-NC (C4582HL070-3) vector is the pJLA-hTNFNC described in the publication number CN1220997A. The ampicillin promoter + ampicillin resistance gene in the pJLA-hTNFNC vector is replaced with the kanamycin promoter + kanamycin gene to construct the C7189424G0-2 of the present invention.

[0043] (promoter+kan_h-TNF-NC). Other elements of the vector of the present invention including the human tumor necrosis factor gene sequence are the same as those of the pJLA-hTNFNC vector described in CN1220997A.

[0044] 1.1 Primer synthesis and PCR amplification

[0045] Design primer sequences, and synthesize primers by automatic synthesizer. After obtaining the target primers, perform PCR amplification. Perform electrophoresis detection on the PCR products to obtain PCR products consistent with the expected size of the target sequence. The gene sequence of promoter+kan is: TGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAG CCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTAGAAAAAC TCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGA CTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGTTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTA CGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTTCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTAC

[0046] 1.2 Ligation transformation and colony screening

[0047] The amplified PCR product was connected with BspHI linearized h-TNF-NC (C4582HL070-3) using GenBuilder, and the resulting connection product was named C7189424G0-2 (promoter+kan_h-TNF-NC). The connection product was transformed into competent cells by heat shock method, and the transformed product was evenly spread on LB plate culture medium containing kanamycin resistance, and the plate was inverted in a 37°C incubator for overnight culture.

[0048] Use a sterile pipette tip to pick up a single colony as a PCR template for colony screening, and transfer it to LB liquid medium containing kanamycin resistance. The primers for bacterial detection are:

[0049] C7189424G0-2_3(5'-TGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTC-3') / C7189424G0-2_12(5'-ATATTCAACGGGAAACGTCGAGGCCGCGATTAAATTCCAACATGGATGCTGATTTATAT GGGTATAAATGGGCTCGCGATAATGTCGGGCAATCAGGTGC-3').

[0050] 1.3 Extraction of plasmids by shaking

[0051] The clones of C7189424G0-2 (promoter+kan_h-TNF-NC) selected by colony screening were numbered E56608, E56609, E56610, E56611, and E56612. The selected clones were inoculated with bacteria and cultured overnight, and the bacteria were collected by centrifugation. The plasmids were extracted, and E56611 and E56612 were sequenced for verification, and E56608, E56609, and E56610 were reserved.

[0052] 1.4 Sequencing and identification

[0053] C7189424G0-2 (promoter+kan_h-TNF-NC) was sequenced and verified, and the sequencing results of the corresponding clones E56611 and E56612 were correct. The primers and sequences are as follows:

[0054] C8950EZSG0-3-seq1(5'-CGGATAAAATGCTTGATGTGT-3')

[0055] C964BQLHG0-5-seq1(5'-ATATGGGTATAAATGGGCTC-3')

[0056] C4061QAVG0-2-seq3(5'-AGGATTAGCAGAGCGAGGTA-3')

[0057] The sequencing results of clone E56612A corresponding to C7189424G0-2 (promoter+kan_h-TNF-NC) were correct. Figure 2 The sequencing results are shown in Figure 2 The determined sequence includes promoter + kanamycin gene + TNF gene sequence.

[0058] 1.5 Enzyme digestion identification

[0059] The plasmid E56612A (C7189424G0-2 (promoter + kan_h-TNF-NC)) was digested with Pvul / Xhol, and the digested product was subjected to gel electrophoresis. The electrophoresis pattern is shown in Figure 3 .

[0060] Conclusion: The theoretical size of clone E56612A (C7189424G0-2 (promoter+kan_h-TNF-NC)) Pvul / XhoI digestion is 2077bp and 3139bp. From top to bottom of Lane 2, the first band is about 3.1kb and the second band is about 2.1kb, which is consistent with the expected results.

[0061] 2. Preparation of recombinant engineered bacteria

[0062] 1. Preparation and detection of glycerol stock of recombinant bacteria

[0063] Clone E56612A was transformed into competent cells HMS174 (DE3) by heat shock method, and the transformed product was evenly spread on LB plate medium containing kanamycin resistance, and the plate was inverted in an incubator at 37°C for overnight culture.

[0064] Single clones were selected and numbered E57209 and E57210, and plasmids were prepared by shaking, followed by sequencing verification and glycerol bacteria detection. The primers and sequences are as follows:

[0065] C4061QAVG0-2-seq3(5'-AGGATTAGCAGAGCGAGGTA-3')

[0066] C7189424G0-2-seq2(5'-GTTATTCATTCGTGATTGCG-3')

[0067] The sequencing results of clones E57209 and E57210 corresponding to C7189424G0-3 (promoter+kan_h-TNF-NC) were correct.

[0068] 260 μL of the original bacterial solution of E57210 (C7189424G0-3 (promoter + kan_h-TNF-NC)) and 260 μL of 50% glycerol were respectively mixed in a sterilized storage tube to prepare glycerol bacteria. 100 μL of the original bacterial solution was taken into a 96-well cell culture plate and the plate was analyzed using an ELISA reader at a wavelength of OD 600 The OD reading of the bacterial solution was 0.3954 under the conditions of 600 The actual value ((microplate reader reading - blank reading) * 5.4) is 1.8889. Then take 1 μL of the glycerol bacteria for plate coating verification and culture overnight. Take it out the next day and observe that the colony morphology is normal, there are no spots, and the number of colonies is greater than 100.

[0069] 2. Identification of recombinant engineered bacteria

[0070] Three batches of engineered bacteria (engineered bacteria samples 1-3) were tested and identified.

[0071] 2.1 The plasmid copy number was detected by PCR, and the results are as follows:

[0072] Table 1

[0073] Sample name Test items Test Results unit Test method / instrument Engineered bacteria sample 1 Plasmid copy number 6 LOG(number of copies, 10) PCR Engineered bacteria sample 2 Plasmid copy number 7 LOG(number of copies, 10) PCR Engineered bacteria sample 3 Plasmid copy number 7 LOG(number of copies, 10) PCR

[0074] 2.2 Real-time fluorescence quantitative PCR was used to detect TNF expression, and the results are as follows:

[0075] Table 2

[0076]

[0077]

[0078] 3. Cultivation and fermentation of recombinant engineered bacteria

[0079] 1. Reagents, culture medium and preparation method:

[0080] 1.1 Primary seed liquid LB medium①: (preparation volume 1200ml)

[0081] Table 3

[0082] Material Name Dosage Material Name Dosage Tryptone 12.0g Sodium chloride 6.0g Yeast Extract 6.0g Purified water Add to 1200ml

[0083] Pour the LB medium for primary seed liquid culture① into a beaker, add purified water and stir to fully dissolve it, and adjust the volume to 1200ml; divide it into 6 1000ml conical flasks (200ml each). Set: 121℃, 30min wet heat sterilization and set aside.

[0084] 1.2 Prescription of Kanamycin Sulfate Solution (preparation volume 5 ml)

[0085] Table 4

[0086] Material Name Dosage Material Name Dosage Kanamycin Sulfate 1g Sterile purified water Add to 5ml

[0087] During the primary seed inoculation process, add 1 g of kanamycin sulfate to 5 ml with sterile purified water in a clean workbench, and add 100 μl of kanamycin sulfate to the LB medium during inoculation.

[0088] 1.3 Secondary seed liquid LB medium (preparation volume 40L)

[0089] Table 5

[0090] Material Name Dosage Material Name Dosage Tryptone 400.0g Sodium chloride 200.0g Yeast Extract 200.0g PPE defoamer 4ml Purified water Add up to 40L NA NA

[0091] After sterilization with purified water in the 75L fermenter, drain the purified water in the tank. Pour the secondary seed liquid LB medium into a container, add purified water and stir to fully dissolve it, then add it to the 75L fermenter, set the volume to a final volume of 40L, set 121℃, 30min wet heat sterilization, cool the medium to 33℃, dispose of 26L of the secondary seed liquid LB medium, and leave 14L of the secondary seed liquid LB medium for standby use.

[0092] 1.4 LB medium for fermentation② (preparation volume 200L)

[0093] Table 6

[0094] Material Name Dosage Material Name Dosage Tryptone 900.0g Yeast Extract 450.0g Disodium hydrogen phosphate dodecahydrate 2100g Potassium dihydrogen phosphate 1200g Dipotassium hydrogen phosphate trihydrate 1572g Ammonium sulfate 360g Ammonium chloride 60g Glycerol 240ml PPE defoamer 20ml Purified water Add up to 200L

[0095] 1.5 Formula of trace elements for fermentation:

[0096] 1.5.1 Trace element solution A (volume 100 ml)

[0097] Table 7

[0098] Material Name Dosage Material Name Dosage Sodium molybdate dihydrate 0.020g Copper sulfate pentahydrate 0.010g Boric acid 0.005g Calcium chloride dihydrate 0.200g Purified water Add to 100mL NA NA

[0099] 1.5.2 Trace element solution B (volume 100 ml)

[0100] Table 8

[0101] Material Name Dosage Material Name Dosage Zinc chloride 0.020g Cobalt chloride hexahydrate 0.040g Purified water Add to 100mL NA NA

[0102] After sterilization with purified water in the 300L fermentation tank, drain the purified water in the tank. Pour the fermentation LB medium into a container and add purified water. Stir to fully dissolve it, then add it to the fermentation tank. Then add 2ml of trace element solution A and 2ml of trace element solution B to the tank, add purified water to make the volume 200L, run the automatic sterilization program of the fermentation tank (set sterilization conditions: 121℃, 30min), and cool the medium to 33℃ after completion.

[0103] 1.6 48L feed medium ③: (prepare 8000ml)

[0104] Table 9

[0105] Material Name Dosage Material Name Dosage Tryptone 800.0g Yeast Extract 400g Purified water Add to 8000mL NA NA

[0106] Pour the feed medium into the feed bottle, dissolve the above ingredients with appropriate amount of purified water, add purified water to make up to 8000ml, and sterilize with wet heat at 121℃ for 30min before use for feed in the fermentation process.

[0107] 1.7 55L feed medium ③: (prepare 5000ml)

[0108] Table 10

[0109] Material Name Dosage Material Name Dosage Tryptone 500.0g Yeast Extract 250g Purified water Add to 5000mL NA NA

[0110] Pour the feed medium into the feed bottle, dissolve the above ingredients with appropriate amount of purified water, add purified water to make up to 5000ml, and sterilize with wet heat at 121℃ for 30min before use for feed in the fermentation process.

[0111] 1.8TES buffer solution formula (preparation volume 20L):

[0112] Table 11

[0113] Material Name Dosage Material Name Dosage Sodium chloride 234g Tris(hydroxymethyl)aminomethane 242g Disodium EDTA 372g Purified water Add to 20L

[0114] Pour the above ingredients into a beaker, dissolve them with an appropriate amount of purified water (80% of the preparation volume), and adjust the pH value to 7.2±0.1 with HCL. Then add purified water to 20L and fine-tune the pH value to 7.2±0.1 for later use.

[0115] 2. Cultivation and fermentation

[0116] 2.1 Primary seed inoculation: Take 5 bottles of 200 ml LB medium, add 100 μl of kanamycin sulfate solution to the LB medium on a clean bench in the inoculation room, and then add 1000 μl of the recombinant engineered bacteria (glycerol bacteria) to prepare for cultivation.

[0117] 2.2 Primary seed culture: After inoculation, the Erlenmeyer flask is placed in a constant temperature culture shaker, set at 33°C and 200rpm, and cultured for 10-12 hours. Then take a sample and measure the OD value of the primary seed liquid. When the OD reaches 1.5, the culture is over. Gram staining should show typical Gram-negative Escherichia coli without any other bacteria.

[0118] 2.3 75L fermentation tank emptying:

[0119] 40 L of purified water was placed in the fermenter, and the fermenter was sterilized at 121.0°C for 30 min, and the fermenter was sterilized.

[0120] 2.4 75L fermentation tank actual consumption:

[0121] Add 40 L of secondary seed culture medium into the fermenter and sterilize at 121.0°C for 30 min.

[0122] 2.5 Level 1 Seed Liquid Bottle

[0123] First-level seed liquid combination bottle: Combine 5 bottles of first-level seed culture solution and pour them into the inoculation bottle. The total volume should be controlled at 1000±50ml.

[0124] 2.6 Inoculation of 75L Fermenter

[0125] Before inoculation, 26L of the secondary seed liquid LB medium in the fermenter was disposed of, and the remaining 14L was used for standby. 1000ml of the cultured primary seed liquid was inoculated by flame method to start secondary culture.

[0126] 2.7 Fermentation in 75L fermenter

[0127] Carry out secondary culture at 33°C and 100-700 rpm for 2-4 hours. 600 When it reaches 0.9-1.8, Gram staining microscopy should show typical Gram-negative Escherichia coli without any other bacteria.

[0128] The cultivation process parameters of the secondary seed liquid 75L fermenter were as follows: temperature: (33±2)℃, rotation speed: 500rpm, OD value: 1.5, cultivation time: 3.5h, tank pressure: 0.2bar, ventilation volume (AIRFL): 50L / min.

[0129] 2.8 75L fermentation tank seed liquid transfer

[0130] When the OD value and microscopic examination are qualified, connect the 75L fermenter discharge pipeline and the 300L fermenter feed pipeline to transfer. Alternatively, transfer to an inoculation bottle, store at 2-6℃, and inoculate within 24 hours.

[0131] 2.9 300L Fermentation Tank Air Disinfection

[0132] 160 L of purified water was placed in the fermenter, and the fermenter was sterilized at 121.0°C for 30 min, and the fermenter was sterilized.

[0133] 2.10 300L fermentation tank

[0134] Add 200 L of fermentation medium into the fermenter, then add 2 ml of trace element solution A and 2 ml of trace element solution B, and sterilize at 121.0°C for 30 min for actual disinfection.

[0135] 2.11 Inoculation of 300L Fermentation Tank

[0136] 15 L of the cultured secondary seed liquid was added into 200 L of fermentation medium that had been sterilized and cooled to 33°C for fermentation culture.

[0137] 2.12 Fermentation in 300L fermenter

[0138] Fermentation was carried out at 33°C, tank pressure: 0.2 bar, ventilation (AIRFL): (50±5) L / min, pH value was controlled between 6.0-7.2, pH could be adjusted with water, dissolved oxygen was not less than 40% (to ensure dissolved oxygen ≥ 40% during fermentation, the speed control range could be adjusted in stages between (200-900) rpm as needed), fermentation was carried out for about 3.5-5.0 hours, OD 600 When the OD reaches 0.8-1.8, raise the temperature to 42℃ for induction, feed at the same time, and continue culturing for about 3.0-5.0 hours. When the OD starts to decrease during the culture process, add an appropriate amount of 5L of prepared culture medium.

[0139] Gram staining microscopy should show typical Gram-negative Escherichia coli without other bacteria. Cool to below 35℃ and centrifuge. 600 >1.4.

[0140] 2.13 300L Fermentation Tank Fermentation Tank

[0141] The discharge port of the fermentation tank is connected to the feed port of the tubular separator, or connected to the feed port of the pre-cooled storage tank. The storage tank discharge port and the feed port of the tubular separator are connected. Open the water supply valve of the tubular separator's chilled water, turn on the tubular separator, maintain the pressure in the tank at 0.2-0.6 bar, slowly open the discharge valve, control the flow rate of the fermentation liquid at about 1.0-2.0L / min per centrifuge, stop stirring when the liquid level in the fermentation tank drops below the lowest stirring blade, and discharge the supernatant through a dedicated pipeline to the inactivation tank for inactivation and then discard. After centrifugation, use a stainless steel scraper to scrape the wet bacteria and detect the expression level.

[0142] 2.14 Bacteria washing:

[0143] Suspend the cells in 3000ml TES solution, gently stir and wash evenly, put into a high-speed refrigerated centrifuge, centrifuge at 6700rpm for 20min at 4℃; the supernatant is clear and transparent, and the supernatant is poured out and discarded after inactivation; repeat the above washing process once more. Wet cells are obtained, and the weight of the wet cells is weighed to detect the expression level.

[0144] 2.15 High pressure homogenization:

[0145] Suspend the bacteria in a TES solution 10 times the volume of the bacteria, adjust the air inlet valve of the high-pressure homogenizer pump motor and the air inlet valve of the discharge pipe so that the pressure of the discharge pipe is within the range of 340-1400 bar to homogenize and break the bacteria to obtain cell breaking liquid. Check that the bacteria are completely broken by microscopic examination.

[0146] 2.16 Crushing liquid separation:

[0147] The cell disruption solution was centrifuged at 4°C and 11,000 rpm for 30 min, the supernatant was collected, and the resulting precipitate was inactivated at 121°C for 30 min and then discarded.

[0148] 2.17 Ammonium sulfate graded protein precipitation:

[0149] After centrifugation, add ammonium sulfate (mass concentration of 50%) (100ml / 29.6g) to the supernatant, fully dissolve it, place it in a refrigerator and stir for 1 hour, the temperature setting is: 4°C; centrifuge after stirring for 1 hour, set the parameters as temperature: 4°C, speed: 11000rpm, centrifugation time: 30min. Collect the supernatant precipitate and discard it, add ammonium sulfate (mass concentration of 10%) (100ml / 7.9g) to the supernatant after harvest again, fully dissolve it and place it in a refrigerator and stir for 1 hour, the temperature setting is: 4°C. Centrifuge after stirring for 1 hour, set the centrifugation parameters as temperature: 4°C, speed: 11000rpm, centrifugation time: 30min. This time the supernatant is discarded, the precipitated protein is collected, the weight of the precipitated protein is weighed, the protein purity is tested, and it is stored at -20°C. The storage period does not exceed 6 months.

[0150] The fermentation test results of three batches are shown below:

[0151] Table 12

[0152]

[0153] 4. Protein purification:

[0154] 10× Buffer A stock solution (prepared 1000ml)

[0155] Table 13

[0156] Material Name Dosage Material Name Dosage Tris 12.11g HCl 8ml±1ml

[0157] After dissolving Tris with an appropriate amount of water for injection (70%-80% of the preparation volume), adjust the pH value to 7.6±0.1 with HCl. Add water for injection to 1000 ml and fine-tune the pH value to 7.6±0.1. Ultrafiltration with an 8K membrane package is performed and sterilized by wet heat sterilization (121°C, 30 min).

[0158] 5× Buffer B stock solution (prepared 1000ml)

[0159] Table 14

[0160] Material Name Dosage Material Name Dosage Tris 6.06g HCl 4ml±1ml NaCl 23.38g NA NA

[0161] Dissolve Tris and NaCl with an appropriate amount of water for injection (70%-80% of the preparation volume), and adjust the pH value to 7.6±0.1 with HCl. Add water for injection to 1000 ml and fine-tune the pH value to 7.6±0.1. Ultrafiltration with an 8K membrane package and wet heat sterilization (121°C, 30 min).

[0162] The protein purification process is as follows Figure 4 shown.

[0163] 1 Ultrafiltration desalination of protein solution:

[0164] 1.1 Before ultrafiltration, pay attention to the number of times the silicone tube is used by the peristaltic pump, and change the contact position between the peristaltic pump head and the silicone tube to avoid fatigue and bursting of the silicone tube. During the ultrafiltration process, the operator should observe the pressure.

[0165] 1.2 Construction of protein solution ultrafiltration device. This device should consist of at least two peristaltic pumps and a membrane package clamp. The membrane package should be cleaned in advance before ultrafiltration and sealed with buffer A solution. The molecular weight range of the membrane package is 5K~10K.

[0166] 1.3 The flow rate of the protein solution adding pump is set to be above 30 ml / min, and the speed of the ultrafiltration peristaltic pump is set to be greater than 30 rpm. After the membrane package is cleaned, the conductivity and pH value of the 1×Buffer A solution at the inlet, outlet and reflux port of the fixture are consistent.

[0167] 1.4 Use 1×Buffer A solution to simulate the protein ultrafiltration process, adjust the pressure at the reflux port of the fixture to about 1.0 bar, the flow rate at the inlet of the fixture to greater than 30 ml / min, place the serum bottle containing the protein solution on the magnetic stirrer, set the rotor speed to greater than 30 rpm, and the difference between the inlet pressure and the reflux pressure should not exceed 10%.

[0168] 1.5 After the simulation is completed, place the three pipelines including the fixture inlet, reflux port and dosing pump inlet tube in the serum bottle containing the protein solution. Turn the diaphragm valves of the fixture inlet, reflux port and outlet to the maximum. Turn on the peristaltic pump connected to the fixture to allow the protein solution to reflux for a while. Slowly tighten the diaphragm valve of the fixture reflux port until the reflux pressure reaches about 1.0 bar. Then turn on the dosing pump to add pre-cooled 1×buffer A solution to the serum bottle containing the protein solution at a flow rate greater than 30 ml / min. Connect the ultrafiltration membrane package fixture outlet to the serum bottle to record the waste liquid capacity.

[0169] 1.6 After ultrafiltration, the conductivity of the protein solution diluted 10 times was tested to be below 1100 μs / cm, and DEAE chromatography was performed.

[0170] 2.DEAE chromatography:

[0171] 2.1 DEAE chromatography uses a 300*750 Hanbang manual chromatography column, loaded with 20.0L of Nanomicro UniGel8-8DEAE filler. Due to the compressibility of the filler, the column height should be 29cm±3cm. Before DEAE chromatography, the column efficiency and symmetry are measured, and the chromatography operation is started after meeting the requirements.

[0172] 2.2 DEAE column pretreatment: Use 0.5 mol / L NaOH at a flow rate of 40 L / h to flush 1 column volume (about 20 L), and then flush with sterile water for injection at 40 L / h until the effluent is neutral.

[0173] 2.3 Balance before loading: Use Buffer A to balance the column at a flow rate of 40 L / h. The balance volume is greater than 7 column volumes. The pH of the outflow liquid is 7.6 ± 0.1, and the conductivity is consistent with the original solution.

[0174] 2.4 Loading and balancing: dilute the qualified ultrafiltrate with Buffer A at a ratio of 1:10, control the conductivity at 550-800us / cm, pause the instrument, replace the Buffer A solution with the diluted sample, and start loading at a flow rate of 20L / h. A loading peak with a platform should appear.

[0175] After loading, Buffer A was used to balance for 2-3 column volumes at a flow rate of 40 L / h until the baseline level was reached.

[0176] 2.5 Elution: Use Buffer B for elution at a flow rate of 20L / h. According to the peak conditions displayed on the computer, collect the outflow peaks at a wavelength of 280nm in segments. Specifically, collect three peaks respectively, collect and temporarily store the first peak. The second peak is the target protein peak, and the third peak is collected and temporarily stored; collect the collected samples in segments with a beaker, and the filling volume is ≤ 2 / 3 of the volume to obtain DEAE sample. Take samples to determine the protein content and perform electrophoresis.

[0177] 2.6 DEAE column sample detection: SDS-PAGE electrophoresis: Check the purity of the collected liquid of the rmhTNF target protein peak, Coomassie brilliant blue or silver staining, and scan after non-reducing electrophoresis. The purity is >80%.

[0178] The results of SDS-PAGE electrophoresis are as follows Figure 5 As shown in the figure, from the test results, peaks 1 and 2 have a large amount of target protein (protein containing ammonium sulfate before ultrafiltration), peak 3 has a small amount of target protein, and peak 4 has a very small amount of target protein. Peaks 1, 2, and 3 are collected and concentrated by ultrafiltration. The protein concentration test results are:

[0179] Table 15

[0180]

[0181] 2.7 DEAE column sample merging: According to the detection results of SDS-PAGE electrophoresis, the TNF effluent peak collection liquid with purity>80% is combined for the next production process (1, 2, 3 collection peaks are combined and ultrafiltration and concentration is performed).

[0182] 3Ultrafiltration concentration:

[0183] 3.1 Preparation for ultrafiltration: The ultrafiltration membrane package is cleaned with sterile water for injection or water for injection within the validity period until it is neutral, disinfected with 0.1 mol / L sodium hydroxide solution, and then flushed with sterile water for injection or water for injection within the validity period until it is neutral, and rinsed with 1L of Buffer A for about 30 minutes.

[0184] 3.2 Ultrafiltration: Concentrate the qualified DEAE column combined liquid through ultrafiltration membrane package to obtain ultrafiltration concentrate.

[0185] 3.3 Cleaning of ultrafiltration membrane: After ultrafiltration, clean the ultrafiltration membrane with 0.1mol / L NaOH solution, flush it to neutrality with sterile water for injection or water for injection within the validity period, and seal it with 0.05mol / L NaOH solution after cleaning.

[0186] 4.S-100 chromatography:

[0187] S-100 chromatography uses a 140*950 Hanbang manual chromatography column, loaded with 10.0L of Nano-Micro NW Super 100 filler. Due to the compressibility of the filler, the column height should be 54cm±3cm. Before S-100 chromatography, the column efficiency and symmetry are measured, and the chromatography operation begins after meeting the requirements.

[0188] 4.1 Treatment of S-100 columns: When using the S-100 column for the first time, rinse more than 1 / 3 column volume with 0.2mol / L NaOH solution at a flow rate of 3L / h to disinfect the column, and then rinse more than 1 column volume with Buffer B at a flow rate of 3L / h. When using it again, you can directly use Buffer B to treat 1 column volume;

[0189] 4.2 Use Buffer A to balance 2-4 column volumes at a flow rate of 1.1-3L / h until the conductivity and pH value of the inflowing and outflowing buffers are consistent. Then it can be used for sample separation.

[0190] 4.3 Load the ultrafiltration concentrate onto the S-100 column balanced as above at a flow rate of 3 L / h. Elute with Buffer B at a flow rate of 3 L / h. Collect the effluent at 280 nm according to the peak conditions displayed by the computer. After the peak is collected, sample and test. Combine the effluents that pass the test. The recombinant modified human tumor necrosis factor stock solution (i.e., rmhTNF stock solution) is obtained when the sample is tested and qualified.

[0191] The results of S-100 protein electrophoresis are as follows Figure 6 As shown, result analysis: From the test results, it can be seen that the S-100 chromatography separation effect is good, and the target band is obvious. Purity HPLC test results: stock solution purity: 98.1%; electrophoresis result: 98.9%, which meets the requirements.

[0192] The above method was used to test the three batches of rmhTNF stock solutions. The test results are shown in the following table:

[0193] Table 16

[0194]

[0195] 4.4 Confirmation of the structure of rmhTNF stock solution

[0196] 4.4.1 C-terminal sequence: The C-terminal sequence of the rmhTNF stock solution protein was analyzed by mass spectrometry. The results showed that the C-terminal amino acid sequences of the three batches of rmh-TNF stock solutions were all: Ser Gly Gln Val Tyr Phe Gly Ile Ile AlaGln.

[0197] 4.4.2 N-terminal sequence: The results showed that the N-terminal amino acid sequences of the three batches of rmh-TNF stock solutions were all: NH 2 -Met-Arg-Lys-Arg-Lys-Pro-Val-Ala-His-Val-Val-Ala-Asn-Pro-GlnAla-Glu-Gly-Gln-Leu, which is consistent with the theoretical sequence.

[0198] 4.4.3 Disulfide bonds: After non-reductive enzymatic hydrolysis and liquid quality testing and analysis of three batches of rmh-TNF stock solutions, one disulfide bond was identified that was consistent with the theoretical disulfide bond pairing pattern.

[0199] Theoretical sequence:

[0200] MRKRKPVAHV VANPQAEGQL QWLNRRANAL LANGVELRDN QLVVPSEGLY

[0201] LIYSQVLFKG QGCPSTHVLL THTISRIAVS YQTKVNLLSA IKSPCQRETP

[0202] EGAEAKPWYE PIYLGGVFQL EKGDRLSAEI NRPDYLDFAE SGQVYFGIIAQ

[0203] 4.5 Adding stabilizer

[0204] Under laminar flow protection, first use a measuring cylinder to measure the volume VO, and add 20% human albumin qualified TNF stock solution at VO / 19. After mixing, sterilize and filter through a disposable 0.22μm filter to obtain the albumin-added recombinant modified human tumor necrosis factor stock solution (i.e., albumin-added TNF stock solution).

[0205] 4.6 Stock solution packaging

[0206] The stock solution with added human albumin is packaged in saline bottles, with each bottle filling no more than 2 / 3 of the total capacity. After sealing, store in a refrigerator at -30℃ or below.

[0207] Experimental Example 1 Determination of plasmid stability and protein expression during recombinant Escherichia coli fermentation

[0208] 1. Experiment on determination of recombinant plasmid loss rate

[0209] Experimental Procedure

[0210] (1) Preparation of Kanamycin-free Plates

[0211] Pour the prepared, sterilized LB solid medium directly into the sterilized culture dish. Pour about 15 ml of medium into each plate on average, mark it (KA+) and wait for it to solidify before use.

[0212] (2) Preparation of Kanamycin-containing plates

[0213] Weigh 20 mg of kanamycin and add 2 ml of phosphate buffer to dissolve it into a kanamycin solution with a concentration of 10 mg / ml. Take 100 ml of LB solid culture medium and melt it in a water bath and cool it to about 50-60°C. Add 0.5 ml of 10 ml of kanamycin solution to make the concentration 50 ug / ml, then mix well and pour into a sterilized culture dish. Pour about 15 ml of culture medium into each plate on average, mark it (KA+) and wait for it to solidify before use.

[0214] (3) Take 0.5 ml of the seed solution, pick a loop with an inoculation loop, and streak it on a plate without kanamycin for culture. Incubate at 37°C for 24 hours.

[0215] (4) After the culture is completed, take two LB medium plates without kanamycin and two LB medium plates containing kanamycin.

[0216] (5) Pick a single colony from the plate with a sterilized toothpick and inoculate it on a plate containing LB medium without kanamycin. Then inoculate it on a plate containing LB medium with kanamycin. Place the inoculated plates in a 37°C incubator and incubate for 24 hours.

[0217] Experimental results: The number of colonies in the plates containing and not containing kanamycin was counted respectively, and the results are shown in the following table.

[0218] Table 17 Statistics of colony counts of recombinant plasmid engineering bacteria cultured overnight

[0219]

[0220]

[0221] Note: Plasmid loss rate = (1-number of colonies on the plate containing kanamycin / number of colonies on the plate without kanamycin) * 100%

[0222] According to the formula calculation, the plasmid loss rates of culture dishes No. 1 and No. 2 are both (1-100 / 100)*100%=0%, and the average value is 0%.

[0223] 2. Determination of target protein expression (SDS-PAGE)

[0224] The fermentation broth obtained from each batch of the fermentation tank 2.13 in the aforementioned recombinant engineering bacteria culture and fermentation project was used for the protein expression determination experiment, and the protein purity after the secondary precipitation with ammonium sulfate was detected by SDS-PAGE method.

[0225] 1. Experimental process

[0226] (1) Preparation of double-layer glass panels

[0227] Take a double-layer glass plate specially used for protein and fix it on the gel-making mold. Pour pure water into the double-layer glass and check whether there is any leakage. If there is no leakage, it means that the double-layer glass is well sealed. Pour out the purified water and use filter paper to absorb the remaining water inside for later use.

[0228] (2) Preparation of separation gel and stacking gel: Prepare separation gel and stacking gel according to the formulas shown in the table below.

[0229] Table 18 Reagent formula for preparing separation gel and stacking gel

[0230]

[0231] Use a pipette to absorb the separation gel and immediately pour it into the double-layer glass plate (be careful to avoid bubbles), until it is about 3 cm from the top of the double-layer glass, then carefully add purified water to cover the separation gel to keep the gel surface flat. Let it stand at room temperature for about 30 minutes to solidify. After the gel surface solidifies, discard the water layer and use filter paper to absorb the remaining water.

[0232] Use a pipette to absorb the concentrated gel and immediately pour it into a double-layer glass plate (added on top of the separation gel) until the top, insert a cleaned loading comb, and let it stand at room temperature for 40 minutes to allow the colloid to solidify.

[0233] (3) Sample loading: Take 60ul of the test sample and add 20ul of the test sample buffer, mix thoroughly, and boil at 100℃ for 5min. Place the treated sample and marker in the gel wells respectively.

[0234] (4) Electrophoresis: Cover the electrophoresis tank, connect the electrophoresis instrument, connect the power supply, turn on the switch, and control the voltage at 80V when starting electrophoresis. When the blue indicator band electrophoreses to the junction of the separation gel and the concentrated gel, control the voltage at 180V until the indicator band migrates to the bottom of the gel, turn off the power supply, and stop electrophoresis. The electrophoresis time is about 80 minutes.

[0235] (5) Dyeing and bleaching

[0236] After electrophoresis, place the electrophoresis gel in a plastic box and place it in the fixative for 60 minutes. Discard the fixative, add Coomassie Brilliant Blue staining solution, and shake the plastic box on a shaker for 60 minutes. Discard the staining solution, add purified water to rinse once, pour out the purified water, add Coomassie Brilliant Blue destaining solution, and shake it on a shaker overnight until the gel base color is almost colorless. Take out the gel and place it in the preservation solution.

[0237] (6) Electrophoresis gel scanning: Scan the electrophoresis gel to obtain the electrophoresis pattern and calculate the protein expression level. The experimental results are as follows:

[0238] Table 19

[0239]

[0240] The fermentation results of each batch are shown in the table above. It can be seen that the plasmid loss rate is 0% and the expression level of the target protein is high.

[0241] Experimental Example 2

[0242] For the protein produced by the fermentation of batch TP20231203, the samples before ultrafiltration desalting, after ultrafiltration desalting, DEAE column loading solution, ultrafiltration waste solution, DEAE column post sample, peak 1, peak 2 and regeneration peak were subjected to SDS-PAGE electrophoresis. The protein content results are shown in Table 20 below. The SDS-PAGE electrophoresis diagram is shown in Figure 7 shown.

[0243] Table 20

[0244]

[0245]

[0246] Results: From the electrophoresis patterns, it can be seen that the patterns before and after desalting ultrafiltration are similar (lanes 1 and 3 from the left), and the protein content determination shows that the total protein content is similar, indicating that ultrafiltration desalting has no effect on the protein content.

[0247] Comparative Example 1

[0248] A comparative experiment on plasmid loss rate was conducted using a strain containing the original plasmid of ampicillin resistance.

[0249] Experimental process:

[0250] (1) Preparation of plates without ampicillin

[0251] Pour the prepared, sterilized LB solid medium directly into the sterilized culture dish. Pour about 15 ml of medium into each plate on average, mark it (AP-) and wait for it to solidify before use.

[0252] (2) Preparation of plates containing ampicillin

[0253] Weigh 91.7 mg of ampicillin sodium and add 9 ml of phosphate buffer to dissolve it into a kanamycin solution with a concentration of 10 mg / ml. Take 100 ml of LB solid culture medium and melt it in a water bath and cool it to about 50-60°C. Add 10 ml of kanamycin solution 1 ml to make the concentration 100 ug / ml, then mix well and pour into a sterilized culture dish. Pour about 15 ml of culture medium into each plate on average, mark it (AP-) and wait for it to solidify before use.

[0254] (3) Take 1 ml of the seed liquid bacteria (engineered bacteria containing the ampicillin resistance plasmid before improvement), pick a loop with an inoculation loop and streak it on a plate without ampicillin for cultivation. Cultivate at 37°C for 24 hours.

[0255] (4) After the culture is completed, take two LB culture medium plates without ampicillin and two LB culture medium plates containing ampicillin.

[0256] (5) Pick a single colony from the plate with a sterilized toothpick and inoculate it on a plate containing LB medium without ampicillin. Then inoculate it on a plate containing LB medium with ampicillin. Place the inoculated plates in a 37°C incubator and incubate for 24 hours.

[0257] Experimental results: The number of colonies in the plates containing and without ampicillin were counted respectively, and the results are shown in the following table.

[0258] Table 21 Ampicillin resistance plasmid engineering bacteria overnight culture plate colony count statistics

[0259]

[0260]

[0261] Note: Plasmid loss rate = (1-number of colonies on the plate containing ampicillin / number of colonies on the plate without ampicillin) * 100%. According to the formula, the plasmid loss rate of culture dish No. 1 = (1-82 / 100) * 100% = 18%, the plasmid loss rate of culture dish No. 1 = (1-88 / 100) * 100% = 12%, and the average value is 15%.

[0262] Therefore, the average plasmid loss rate of ampicillin-resistant engineered bacteria is 15%, which is relatively unstable. Compared with the recombinant plasmid of kanamycin resistance, its plasmid loss rate is much higher, indicating that the presence of kanamycin resistance gene is indeed conducive to increasing the stability of the recombinant plasmid.

[0263] Comparison of fermentation methods before and after improvement of comparative example 2

[0264] The kanamycin-resistant engineered bacteria were fermented for a total of 12 batches, including 2 batches with a fermentation volume of 50 liters and 10 batches with a fermentation volume of 200 liters. The strain before improvement was an engineered bacterium with an ampicillin-resistant expression vector (the strain after improvement was an engineered bacterium with a kanamycin-resistant expression vector)

[0265] The steps of the fermentation process were the same as the original process, with the following differences: (1) fermentation temperature: 30°C before improvement and 33°C after improvement; (2) inoculation volume: 2000ml before improvement and 15000ml after improvement; (3) rotation speed: 200rpm / min before improvement and 500rpm / min after improvement. The specific conditions and results are compared in the table below.

[0266] Table 22 Comparison of conditions before and after fermentation process improvement

[0267]

[0268]

[0269] Table 23 Comparison of fermentation conditions and results of multiple batches

[0270]

[0271]

[0272] Results: The inoculation amount was increased, the temperature was raised, and the culture time was extended. Through the process optimization in three aspects, more fermentation bacteria were obtained and the yield was increased.

[0273] Compared with the fermentation process before improvement, the fermentation temperature of the improved fermentation process is increased, and the growth rate is faster than the original temperature, so the density (OD value) is increased, but it does not affect the product quality. The plasmid loss rate and expression amount are better than the penicillin resistance gene fermentation at the original temperature. Therefore, when the kanamycin resistance gene engineering bacteria are fermented, the growth is promoted by increasing the temperature, so 33℃ and 15L inoculation volume are determined, and the process is stable for multiple batches, the quality is stable, and the yield is greater than the original engineering bacteria fermentation product.

[0274] Through multiple batches of fermentation, it was found that the plasmid stability of the kanamycin-resistant engineered bacteria was very good, and no plasmid was lost. The fermentation expression was higher than before, all greater than 40%. Since there was no plasmid loss, that is, each engineered bacterium carried TNF, the growth rate was slightly slower than that of the penicillin-resistant engineered bacteria. By adjusting the temperature, the growth rate was basically the same as before, slightly faster. After research, the process parameters were determined to be the parameters used in batches TF20231203 and TF20231204.

[0275] Comparative Example 3 Comparison of purification methods before and after improvement

[0276] (1) For the ammonium sulfate precipitation after the bacteria were broken, the ammonium sulfate was removed and the original dialysis process was replaced by ultrafiltration desalination, which greatly shortened the time and improved the activity. (2) The purification DEAE filler and S00 filler were changed from the original GE imported gel to the domestic Nawei gel. Due to the change of filler, the filler properties also changed accordingly. (3) Through multiple batches of research, the purification method was adjusted, the pH was increased to pH7.6, which was easy to adsorb and increase the yield. The elution flow rate was also adjusted according to the filler properties. The purification was carried out using the changed purification parameters. The process was stable and the product quality was good. The final product purity HPLC 99.5%, electrophoresis purity 99%. Therefore, using the changed domestic filler and process parameters, the purification process was stable, the yield exceeded the penicillin-resistant engineered bacteria purification product, and the quality met the standards. The specific differences between the improved purification process and the original process are shown in the table below.

[0277] Table 24 Comparison of purification process parameters before and after improvement

[0278]

[0279]

[0280] Table 25 Comparison of purification equipment fillers before and after improvement

[0281]

[0282]

[0283] 1. The purification scheme of the present invention was used to carry out experiments in different batches, and the results of the rmh-TNF stock solution intermediate were compared and analyzed as follows:

[0284] Table 26

[0285]

[0286] Result analysis: In the above table, TP20231003, TP20231004, and TP20231101 are ampicillin engineered bacteria batches, and TP20231202 is a kanamycin engineered bacteria batch. Judging from the results, high-purity proteins were obtained in accordance with the requirements.

[0287] 2. Comparative analysis of the results of rmh-TNF stock solution plus human albumin, the results are as follows:

[0288] Table 27

[0289]

[0290]

[0291] Result analysis:

[0292] Result analysis: In the above table, TP20231003, TP20231004, and TP20231101 are ampicillin engineered bacteria batches (dialysis), and TP20231202 (JS) is a kanamycin engineered bacteria batch (ultrafiltration desalination). From the results, it can be seen that the product activity is improved after ultrafiltration desalination is used instead of dialysis.

[0293] The potency of the stock solution produced by penicillin-resistant genetically engineered bacteria is 1.7*10 8 The stock solution produced by the kanamycin-resistant genetically engineered bacteria in the present invention has a potency of 2.0*10 8 Above, it can reach 3.73×10 8 , the product activity is greatly improved.

[0294] The above is only a preferred embodiment of the present invention, and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment as above, it is not used to limit the present invention. Any technician familiar with the present invention can make some changes or modify the technical contents suggested above into equivalent embodiments without departing from the scope of the technical solution of the present invention. However, any simple modification, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention still fall within the scope of the solution of the present invention.

Claims

1. A kanamycin-resistant tumor necrosis factor recombinant expression vector, characterized in that: The human tumor necrosis factor gene or the recombinant human tumor necrosis factor gene and the kanamycin gene with a promoter are inserted into the Escherichia coli temperature-sensitive expression vector lacking the resistance gene.

2. The kanamycin-resistant tumor necrosis factor recombinant expression vector according to claim 1, characterized in that: The Escherichia coli temperature-sensitive expression vector lacking a resistance gene is a pJLA503 expression vector that does not contain a resistance gene.

3. The kanamycin-resistant tumor necrosis factor recombinant expression vector according to claim 1 or 2, characterized in that: The kanamycin-resistant tumor necrosis factor expression vector is based on the pJLA-hTNFNC expression vector, and the ampicillin gene fragment in the pJLA-hTNFNC expression vector is replaced by the kanamycin gene fragment with a promoter.

4. The kanamycin-resistant tumor necrosis factor recombinant expression vector according to any one of claims 1 to 3, characterized in that: The amino acid sequence corresponding to the recombinant human tumor necrosis factor has a total of 151 amino acids, and compared with the prototype human tumor necrosis factor, the amino acid residues 1 to 7 at the amino terminus are missing, the 8th, 9th, and 10th amino terminus are replaced by Arg, Lys, and Arg, and at least one of Ala and Leu at the carboxyl terminus is replaced by one of Gln, Ser, Gly, Thr, Tyr, and Asn.

5. A method for constructing a kanamycin-resistant tumor necrosis factor recombinant expression vector according to any one of claims 1 to 4, characterized in that: include: The kanamycin gene and human tumor necrosis factor gene or recombinant human tumor necrosis factor gene fragment with a promoter are amplified and inserted into a temperature-sensitive expression vector of Escherichia coli lacking a resistance gene by means of enzyme cutting and ligation.

6. A recombinant bacterium comprising the kanamycin-resistant tumor necrosis factor recombinant expression vector according to any one of claims 1 to 4.

7. The recombinant bacterium according to claim 6, characterized in that The recombinant bacteria is Escherichia coli.

8. The recombinant bacterium according to claim 6, characterized in that The recombinant bacterium was Escherichia coli HMS174 (DE3).

9. Use of the kanamycin-resistant tumor necrosis factor recombinant expression vector according to any one of claims 1 to 4 or the recombinant bacterium according to any one of claims 6 to 8 in producing tumor necrosis factor.

10. Use of the kanamycin-resistant tumor necrosis factor recombinant expression vector according to any one of claims 1 to 4 or the recombinant bacteria according to claims 6 to 8 in increasing the production of tumor necrosis factor.